XORTX Therapeutics Inc.
XRTX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -18.58% | 4.23% | 5.50% | -9.19% | -0.77% |
| Depreciation & Amortization | 6.97% | 56.97% | 3.13% | -51.95% | 7.96% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.68% | -45.32% | -37.26% | -63.12% | -72.40% |
| Operating Income | 32.68% | 45.32% | 37.26% | 63.12% | 72.40% |
| Income Before Tax | -95.46% | 55.98% | 110.05% | -64.79% | 204.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.46% | 55.98% | 110.05% | -64.79% | 204.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.46% | 55.98% | 110.05% | -64.79% | 204.65% |
| EBIT | 32.68% | 45.32% | 37.26% | 63.12% | 72.40% |
| EBITDA | -21.95% | 45.42% | 39.14% | 62.44% | 72.67% |
| EPS Basic | -97.23% | 69.69% | 106.92% | -30.88% | 183.23% |
| Normalized Basic EPS | -97.23% | 69.68% | 106.92% | -30.89% | 183.22% |
| EPS Diluted | -97.24% | 69.82% | 106.89% | -30.81% | 183.18% |
| Normalized Diluted EPS | -97.23% | 69.68% | 106.92% | -30.89% | 183.22% |
| Average Basic Shares Outstanding | 63.88% | 45.27% | 45.27% | 25.91% | 25.74% |
| Average Diluted Shares Outstanding | 63.88% | 45.27% | 45.27% | 25.91% | 25.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
